



an Open Access Journal by MDPI

## Antibody Drug Discovery for Cancer

Guest Editor:

### Dr. Junquan Liu

The University of Texas Health  
Science Center at Houston, 1825  
Pressler St, 501R, Houston, TX  
77030, USA

Deadline for manuscript  
submissions:

**31 May 2024**

### Message from the Guest Editor

Dear Colleagues,

Characterized by an excellent specificity, high-level affinity, long serum half-life, and immune effector function, antibodies have been a powerful weapon against cancer since the approval of the first antibody drug (rituximab) in 1997. Some alternative formats for approved antibody drugs include antibody-drug conjugates and bispecific antibodies. The successful application of antibody drugs in oncology has encouraged the development of next-generation antibodies with an enhanced response.

This Special Issue aims to publish original research and review articles focused on (but not limited to) the development of new monoclonal antibodies, nanobodies, ADCs, and bispecific antibodies for cancer treatment. Meanwhile, papers related to the translation of antibody drugs and evaluations in clinical trials are welcomed.



[mdpi.com/si/190636](https://mdpi.com/si/190636)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)